Despite improved survival in recent years, long-term outcomes in patients surviving progressive multifocal leukoencephalopathy (PML) beyond the first year remain poorly defined. This international multicentre retrospective study aimed to characterize the 3-year prognosis of patients with PML who had survived at least 1 year, identify factors associated with favourable outcomes and late mortality, and determine recurrence rate. Data were collected through standardized questionnaires across 41 centres in 11 countries. Patients were eligible if they met the 2013 Diagnostic Criteria for Definite PML of the American Academy of Neurology, survived at least 1 year after diagnosis, and had documented follow-up 3 years after diagnosis. Demographic, clinical, virological and radiological data were retrieved at diagnosis, 1 year and 3 years. Functional status was assessed using the modified Rankin Scale, with scores of 0–2 defining a favourable outcome. Generalized linear mixed models identified independent predictors of 3-year functional status and late mortality. Of 1877 screened cases, 245 patients met inclusion criteria. The most common underlying causes of immunosuppression were HIV infection (48%), autoimmune/inflammatory diseases (26%) and haematological malignancies (18%). At 3 years, 220 patients (89.8% of the cohort) were alive and 188 (85.5% of survivors) had neurological sequelae, most frequently motor or cognitive impairment. Overall, 112/245 (45.7%) achieved a favourable functional outcome. HIV-associated PML [odds ratio (OR) 2.36, 95% confidence interval (CI) (1.05–5.28)] was associated with a favourable outcome, whereas higher modified Rankin Scale score at diagnosis [OR 0.48, 95% CI (0.35–0.66)] and higher number of affected brain regions on baseline MRI [OR 0.78, 95% CI (0.64–0.95)] were independently associated with poorer functional outcome. Among variables collected 1 year after diagnosis, good functional status at that time was significantly associated with long-term favourable outcome [OR 0.01, 95% CI (<0.01–0.03)]. Twenty-five patients (10.2%) died after the first year, with mortality associated with higher lesion burden at diagnosis and primary immunodeficiency as underlying disease. Even beyond the first year, PML remained the leading cause of death (11/25). Recurrence occurred in seven patients (2.9%) and was almost always fatal (6/7). This study provides a comprehensive evaluation of long-term outcomes among survivors of PML. These findings present a nuanced picture: while most remain neurologically impaired, nearly half achieve functional independence at 3 years. The results emphasize the prognostic relevance of the initial clinical and radiological burden and early functional trajectory and highlight the need for research into mechanisms driving disease recurrence.